Science
Andrew Lane: Thrilled to Share Our Clinical Trial of the TAG-AZA-VEN triplet for BPDCN
Andrew Lane/LinkedIn

Andrew Lane: Thrilled to Share Our Clinical Trial of the TAG-AZA-VEN triplet for BPDCN

Andrew Lane, Chief of Hematologic Neoplasia Division at Dana-Farber Cancer Institute, shared a post on X:

“Thrilled to share our clinical trial of the TAG-AZA-VEN triplet for BPDCN published today in Blood Journals Portfolio. Team effort! New option for patients- important.

Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm”

Title: Tagraxofusp, Azacitidine, and Venetoclax in Blastic Plasmacytoid Dendritic Cell Neoplasm

Authors: Andrew A. LaneCorresponding Author, Marlise R. Luskin, Julia H. Keating, Nicole R. LeBoeuf, Jacqueline S. Garcia, Shai Shimony, Rebecca Leonard, Adon Goodpaster, Theresa Nguyen, Ilene Galinsky, Ashleigh Eberly Puleo, Naval G Daver, Nitin Jain, Guillermo Garcia-Manero, Hagop M Kantarjian, Marina Konopleva, Anthony S. Stein, Naveen Pemmaraju

Read the Article

Andrew Lane

Other articles featuring Andrew Lane on OncoDaily.

Adon Goodpaster Andrew A. LaneCorresponding Author Andrew Lane Andy Lane Anthony S. Stein Ashleigh Eberly Puleo cancer Guillermo Garcia-Manero Hagop M. Kantarjian Ilene Galinsky Jacqueline S. Garcia Julia H. Keating Marina Konopleva Marlise R. Luskin Naval G Daver Naveen Pemmaraju Nicole R LeBoeuf Nitin Jain OncoDaily Oncology Rebecca Leonard Shai Shimony Theresa Nguyen